AI Science Tracker

Deep-learning virtual screening finds antibacterial hits in over one billion compounds

Genentech Research and Early Development; NVIDIA; Mila–Université de Montréal collaborators · 24 Oct 2025 · medicine

Discovery

Deep-learning virtual screening finds antibacterial hits in over one billion compounds

Genentech and collaborators trained the deep-learning model GNEprop on high-throughput screening data and screened more than 1.4 billion synthetically accessible molecules. In follow-up experiments, 82 selected compounds showed antibacterial activity against the sensitized E. coli ΔtolC strain; the paper reports a 90-fold higher hit rate than the training screen and describes chemically diverse hits, some with activity beyond that strain and validated biological targets.

Technology: GNEprop deep-learning antibacterial activity predictor

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: In follow-up experiments, 82 selected compounds showed antibacterial activity against the sensitized E. coli ΔtolC strain; the paper reports a 90-fold higher hit rate than the training screen and describes chemically diverse hits, some with activity beyond that strain and validated biological targets.
  • Still unknown: The 82 confirmed hits were tested for single-dose activity against the sensitized E. coli ΔtolC screening strain; this is not evidence that all 82 work against wild-type bacteria or in infections. The 90-fold improvement refers to hit rate relative to the HTS training experiment. Some additional compounds were selected for dose-response testing; do not imply all virtual hits were validated. A publisher correction fixed a coauthor’s misspelled first name and did not change results.
  • AI role: GNEprop was trained on approximately two million small molecules screened against E. coli ΔtolC and used to rank a much larger synthetically accessible library for experimental prioritization. The follow-up assays confirmed antibacterial activity for 82 compounds; biological characterization also investigated specific targets.

Evidence sources: https://www.nature.com/articles/s41587-025-02814-6

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 38 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.